Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine Release (Storm) Syndrome" Caused by SARS-CoV-2?
CONCLUSION: Pentoxifylline and oxypurinol are licensed drugs used for diseases other than COVID-19 and, therefore, phase I clinical trials would not be necessary for administration to SARS-CoV2- infected people. It would be worth trying their potential effects against hyperinflammatory response to SARS-CoV2 infection.
PMID: 32787748 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: López-Iranzo FJ, López-Rodas AM, Franco L, López-Rodas G Tags: Curr Pharm Des Source Type: research
More News: Clinical Trials | COVID-19 | Drugs & Pharmacology | Genetics | Pancreatitis | Pandemics | Respiratory Medicine | SARS